Yurpeak 7.5mg KwikPen

Yurpeak 7.5mg KwikPen is a prescription injectable medicine containing Tirzepatide 7.5mg as its active pharmaceutical ingredient. It belongs to the dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist class. The medicine is administered subcutaneously once weekly and is used in the management of adults with type 2 diabetes mellitus and chronic weight management in eligible adults.

The KwikPen is a prefilled, multi-dose injection device designed for single-patient use. Each pen contains four fixed weekly doses. Yurpeak is available in different strengths, including 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg and 15mg.

Composition and Drug Classification

Brand Name: Yurpeak

Active Ingredient: Tirzepatide

Strength: 7.5mg per 0.6ml dose

Dosage Form: Solution for injection

Administration Route: Subcutaneous injection

Therapeutic Class: Antidiabetic agents

Drug Class: Dual GIP and GLP-1 receptor agonist

Administration Frequency: Once weekly

Uses and Therapeutic Indications

Tirzepatide is indicated as an adjunct to diet and physical activity for improving blood glucose control in adults with type 2 diabetes mellitus. It helps regulate blood glucose levels through its effects on insulin secretion and glucagon activity.

It is also indicated for chronic weight management in adults with obesity (BMI of 30 kg/m² or higher), or overweight individuals (BMI of 27 kg/m² or higher) with at least one weight-related medical condition. Treatment should be considered as part of a comprehensive management programme that includes appropriate dietary and physical activity measures.

Mechanism of Action

Tirzepatide works by activating two incretin hormone receptors: GIP and GLP-1. These hormones play important roles in regulating glucose metabolism and appetite.

Its mechanism of action includes:

Stimulating insulin secretion in a glucose-dependent manner.

Reducing glucagon secretion when blood glucose levels are elevated.

Delaying gastric emptying, particularly during initial treatment.

Influencing appetite regulation and food intake.

Supporting improvements in blood glucose control and body weight management.

These combined effects contribute to its therapeutic role in type 2 diabetes and chronic weight management.

Dosage and Administration

Yurpeak 7.5mg KwikPen is administered as a subcutaneous injection once weekly, according to the prescribing healthcare professional's instructions. It can generally be administered at any time of the day, with or without meals.

The abdomen, thigh or upper arm are commonly used injection sites. Injection sites should be rotated regularly to reduce the possibility of local injection-site reactions.

The 7.5mg strength is part of an individualised dose-escalation schedule. Treatment generally begins with a lower strength, followed by gradual adjustments depending on tolerability and clinical response. Patients should not change their prescribed dose independently.

Possible Side Effects

Common adverse reactions associated with tirzepatide include:

Nausea and vomiting

Diarrhoea or constipation

Abdominal discomfort

Decreased appetite

Indigestion

Injection-site reactions

Less common but potentially serious complications include pancreatitis, severe gastrointestinal reactions, gallbladder problems, dehydration-related kidney complications and hypoglycaemia, particularly when used with insulin or insulin secretagogues.

Persistent or severe symptoms require prompt medical assessment.

Warnings and Precautions

Tirzepatide should be used under appropriate medical supervision. Patients should inform their healthcare professional about existing medical conditions, pregnancy, planned pregnancy, breastfeeding and all concomitant medications.

Special consideration is required in patients with a history of pancreatitis, significant gastrointestinal disease or diabetic retinopathy. Tirzepatide may affect the absorption of certain oral medicines because it delays gastric emptying.

Storage Information

Yurpeak KwikPen should generally be stored under refrigerated conditions at 2°C to 8°C and must not be frozen. Protect the medicine from excessive heat and direct light. Always follow the storage instructions supplied with the specific product packaging and patient information leaflet.

Frequently Asked Questions

1. What is Yurpeak 7.5mg KwikPen used for?

It is used as part of treatment for type 2 diabetes and chronic weight management in eligible adults.

2. What is the active ingredient in Yurpeak?

The active pharmaceutical ingredient is tirzepatide.

3. How frequently is Yurpeak administered?

It is administered once weekly by subcutaneous injection, as prescribed by a healthcare professional.

4. Can Yurpeak 7.5mg be used as an initial dose?

The 7.5mg strength is not the usual starting dose. Treatment generally begins at a lower strength and is adjusted gradually under medical supervision.